Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.

Autor: Bermúdez-Pirela V; Endocrine and Metabolic Diseases Research Center Dr. Félix Gómez, University of Zulia, School of Medicine, Maracaibo, Venezuela. vbermudez@hotmail.com, Souki A, Cano-Ponce C, Bermúdez-Arias F, Mengual-Moreno E, Leal-Gonzalez E, Lemus-Antepaz M, de Bravo MC, de Díaz AA, de Pirela NL, Cano-Peñaloza R, Puche-Medina G, Arraiz N, Reyna-Villazmil N, Contreras F, Israili ZH, Valasco M

Publikováno v: American journal of therapeutics [Am J Ther] 2007 Mar-Apr; Vol. 14 (2), pp. 213-20.